Literature DB >> 1287679

Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome.

R Klein1, M Bänsch, P A Berg.   

Abstract

The fibromyalgia syndrome (FMS) is a non-articular rheumatic disorder associated with disturbances in serotonin metabolism. In order to evaluate whether patients with FMS suffer from an autoimmune disorder, we tested sera from 50 clinically well-defined FMS patients for non-organ-specific and organ-specific antibodies by enzyme-linked immunosorbent assay and immunofluorescence test. Common antibodies against nuclei, mitochondria, and microsomes were not increased in these patients compared to healthy controls. However, 74% had antibodies against serotonin and gangliosides. The clinical and diagnostic relevance of these antibodies is supported by the absence of anti-serotonin antibodies in other rheumatic disorders such as rheumatoid arthritis, polymyalgia rheumatica, and collagen diseases. These antibodies may belong to the group of antireceptor antibodies, considering the fact that gangliosides are an important component of the serotonin receptor. It remains to be determined whether these antibodies are of pathogenetic relevance, interfering with serotonin binding and thereby inducing symptoms associated with FMS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287679     DOI: 10.1016/0306-4530(92)90017-2

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  8 in total

Review 1.  Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide.

Authors:  Salih Ozgocmen; Huseyin Ozyurt; Sadik Sogut; Omer Akyol
Journal:  Rheumatol Int       Date:  2005-11-20       Impact factor: 2.631

Review 2.  Status of immune mediators in fibromyalgia.

Authors:  Ali Gur; Pelin Oktayoglu
Journal:  Curr Pain Headache Rep       Date:  2008-06

3.  [Clinical features, pathophysiology and treatment of fibromyalgia.].

Authors:  H C Müller-Busch
Journal:  Schmerz       Date:  1994-09       Impact factor: 1.107

4.  A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids.

Authors:  R Olin; R Klein; P A Berg
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

5.  A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia-myalgia syndrome.

Authors:  R Klein; P A Berg
Journal:  Clin Investig       Date:  1994-07

6.  Immune System Sex Differences May Bridge the Gap Between Sex and Gender in Fibromyalgia.

Authors:  Irene Meester; Gerardo Francisco Rivera-Silva; Francisco González-Salazar
Journal:  Front Neurosci       Date:  2020-01-17       Impact factor: 4.677

Review 7.  Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome.

Authors:  Dina Dadabhoy; Leslie J Crofford; Michael Spaeth; I Jon Russell; Daniel J Clauw
Journal:  Arthritis Res Ther       Date:  2008-08-08       Impact factor: 5.156

8.  Fibromyalgia and Depression in Women: An 1H-NMR Metabolomic Study.

Authors:  Carmen Marino; Manuela Grimaldi; Paola Sabatini; Patrizia Amato; Arianna Pallavicino; Carmen Ricciardelli; Anna Maria D'Ursi
Journal:  Metabolites       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.